In case you missed it: Feb. 7 to Feb. 11

Article

A look back on this week's news.

Optimal prenatal opioid use disorder care may reduce odds of preterm birth

An oral concurrent session at SMFM’s 42nd Annual Pregnancy Meeting highlighted an analysis of pregnancy outcomes after optimal prenatal opioid use disorder care.

Read more

Marijuana exposure during pregnancy may increase adverse birth outcomes

A review and meta-analysis in JAMA Network Open revealed women exposed to marijuana in pregnancy were at significantly increased risk for adverse neonatal outcomes, including low birth weight, small for gestational age, and preterm delivery.

Read more

A noninfectious "infection" after cesarean delivery

Experts evaluate 3 clinical scenarios and determine the appropriate course of action.

Read more

CooperSurgical to acquire the Cook Medical’s Reproductive Health division

CooperSurgical, Inc, a global provider of health products for women, babies, and families, announced Monday plans to acquire the Reproductive Health division of Cook Medical, a manufacturer for minimally invasive medical devices in the fertility, obstetrics, and gynecology markets.

Read more

The current state of uterine fibroid care

“Over 70% of women are estimated to develop uterine fibroids by age 50,” said senior author Irene Aninye, PhD, chief science officer for the Society for Women’s Health Research (SWHR) in Washington, D.C. “Fibroids are a complex condition that can range from being asymptomatic to having deleterious effects on a woman’s health and quality of life.”

Read more

Recent Videos
COVID-19 Therapy Roundtable: Defining the virus today and treatment options | Image Credit: © Production Perig - © Production Perig - stock.adobe.com.
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.